U.S. Market Community

O Futuro da Pfizer (PFE): Uma Narrativa de Transição e Resiliência No final de 2025, a Pfizer Inc. (PFE) encontra-se em um momento pivotal de sua história.Read more

Eli Lilly’s 2026 story is the story of a company that transitioned from a "Pharmaceutical Giant" to a "Global Health Utility." Two years ago, investors were skeptical that Lilly could manufacture enough of its GLP-1 drugs to meet the world’s insatiable demand for weight loss. Today, in 2026, those doubts have been incinerated.Read more

Investment thesis Apple is a mature but exceptionally durable compounder. While iPhone unit growth is structurally limited, Apple’s ecosystem, pricing power, and expanding high-margin Services segment support steady revenue growth and faster earnings and free cash flow growth.Read more

Just about 6 years ago when oil was just about worthless I bought 100,000 worth of oil companies. I looked for the cheapest at the time which was OXY trading just around $9.00 to $10.00 a share.Read more

Business Model – Company value: Strong; Buffett’s preferred: Simple and understandable; Status: ✅; Explanation: Global packaging leader where the merger with Berry Global consolidates market share in essential consumer sectors. Economic Moat – Company value: Strong; Buffett’s preferred: Strong and durable advantages; Status: ✅; Explanation: Significant economies of scale and proprietary know‑how, with the announced 1‑for‑5 reverse stock split signaling continued restructuring of the combined entity.​ Management Quality – Company value: Moderate; Buffett’s preferred: Shareholder‑friendly; Status: ⚠️; Explanation: Dividend commitment and high yield support income investors, but recent complex M&A and dilution weigh on capital allocation quality.​ Return on Equity – 10‑year average: 23.5%; Buffett’s preferred: Above 15%; Status: ✅; Explanation: Long‑term average ROE remains excellent, though the larger equity base post‑merger will likely dilute future ROE levels.​ Return on Equity – Current: 4.2%; Buffett’s preferred: Above 15%; Status: ❌; Explanation: TTM ROE has dropped sharply to about 4.2% because of merger‑related expenses and the much higher reported equity balance around 11.7 billion dollars.​ Operating Margin – 10‑year average: 11.2%; Buffett’s preferred: Above 12%; Status: ⚠️; Explanation: Historical operating margins average roughly 11%, slightly below Buffett’s preferred threshold for high‑quality manufacturers.​ Operating Margin – Current: 9.8%; Buffett’s preferred: Above 12%; Status: ❌; Explanation: Current operating margin is under pressure around 10% due to integration costs and softer volumes.​ Debt to Equity Ratio – Company value: 1.27; Buffett’s preferred: Below 0.5; Status: ❌; Explanation: Financial leverage is high, with total debt estimated near 14.9 billion dollars versus equity of about 11.7 billion dollars.​ Net Debt to EBITDA – Company value: 3.4x; Buffett’s preferred: Below 2.0x; Status: ❌; Explanation: Net leverage of roughly 3.4 times EBITDA is elevated and implies cash flow must prioritize deleveraging over shareholder returns.​ Current Ratio – Company value: 1.20; Buffett’s preferred: Above 1.5; Status: ⚠️; Explanation: Liquidity is somewhat tight at about 1.2 times current liabilities, leaving limited buffer despite steady operating cash flow.​ Free Cash Flow – 5‑year average: 815 million dollars (described as volatile); Buffett’s preferred: Consistent and growing; Status: ⚠️; Explanation: Five‑year average FCF is solid but TTM free cash flow of roughly 725 million dollars is depressed by integration and transaction costs.​ Earnings Growth – 10‑year CAGR: 2.8%; Buffett’s preferred: Above 10%; Status: ❌; Explanation: Over the past decade earnings have grown in the low single digits, reflecting a mature, slow‑growing packaging market.​ Dividend Yield – Current: 6.29%; Buffett’s preferred: Above 4%; Status: ✅; Explanation: The stock offers an attractive yield above 6%, though the GAAP payout ratio currently exceeds 100% of reported earnings.​ Dividend Growth Streak – Company value: 25+ years; Buffett’s preferred: At least 10 years; Status: ✅; Explanation: Including the Bemis legacy record, Amcor has raised its dividend for more than 25 consecutive years and is recognized among dividend growth names.​ Price to Earnings Ratio – Current TTM: 27.53; Buffett’s preferred: Below 15; Status: ❌; Explanation: Using GAAP EPS of 0.30 dollars, the shares trade at about 27.5 times earnings, which is expensive against Buffett’s value threshold.​ Intrinsic Value (DCF) per share – Estimate: 4.85 dollars; Buffett’s preferred: Not applicable; Status: —; Explanation: A discounted cash flow model using TTM FCF of about 725 million dollars, 0% growth, 9% discount rate and 2.5% terminal growth yields intrinsic value around 4.85 dollars per share.​ Intrinsic Value (P/E) per share – Estimate: 9.60 dollars; Buffett’s preferred: Not applicable; Status: —; Explanation: Applying a 10‑year median P/E of about 18 times to normalized EPS of 0.53 dollars implies fair value near 9.60 dollars per share.​ Intrinsic Value (P/B) per share – Estimate: 12.73 dollars; Buffett’s preferred: Not applicable; Status: —; Explanation: Using an industry median price to book near 2.5 times and current book value of roughly 5.09 dollars per share yields intrinsic value around 12.73 dollars.​ Current Stock Price – Company value: 8.26 dollars; Buffett’s preferred: Not applicable; Status: —; Explanation: The latest close on December 24, 2025 shows Amcor trading at about 8.26 dollars per share.​ Margin of Safety – Range: minus 70% to plus 35%; Buffett’s preferred: Above 25%; Status: ⚠️; Explanation: Relative to the three valuation methods, the stock looks overvalued versus DCF but undervalued versus P/B, producing a wide margin‑of‑safety range from negative 70% to positive 35%.​ Final Recommendation – Company value: HOLD; Buffett’s preferred: Not applicable; Status: ⚠️; Explanation: The shares offer a high yield and appear cheap on asset and normalized earnings metrics, but weak current ROE and high leverage suggest caution until merger synergies clearly lift EPS.Read more

Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more

I am NOT an expert. The only point I make is that all of the recent price targets published were PRIOR to the earnings announcements, many of which put a $300 price target, before the blowout earnings numbers were known.Read more

Core Fundamental Data Alexandria Real Estate Equities (NYSE: ARE) is a specialized life science REIT with a highly concentrated portfolio of laboratory and office real estate. As of September 30, 2025, total shareholders’ equity amounted to $16,639 million.Read more

Exceptional investments are often hiding behind familiar labels. Hotel101 Global Holdings may appear, at first glance, to be just another hotel company.Read more